drugset
drugset / Trial / NCT04428255

A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP

NCT04428255 ↗

Phase 2/3 Completed 36 enrolled Harbour BioMed (Guangzhou) Co. Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To select a dose and to make a decision for Phase 3 study

Timeline

Start
2020-07-24
Primary completion
2021-08-10
Completion
2021-08-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Batoclimab Monoclonal antibody — Intravenous

Indications

autoimmune thrombocytopenic purpura